This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Mallinckrodt Pharmaceuticals.
incremental cost-effectiveness ratio
Reference
Hunter SF, et al. Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis. ClinicoEconomics and Outcomes Research : 11 Oct 2021. Available from: URL: https://doi.org/10.2147/CEOR.S330118
Rights and permissions
About this article
Cite this article
Repository corticotropin injections appear to be cost effective for MS in the USA. PharmacoEcon Outcomes News 890, 24 (2021). https://doi.org/10.1007/s40274-021-08147-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08147-y